Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in mild-moderate COVID-19
NCT04705844Phase 3Withdrawn
- Sponsor
- Resilience Government Services
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of adalimumab in coronavirus disease 2019 (COVID-19), sponsored by Resilience Government Services. Planned start Sep 2021; status: withdrawn.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04705844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705844.